Structure Therapeutics (GPCR) closed at $22.01 on Oct 19, 2026, up 4.4% on the day. The stock is down 37.1% over the past month, down 55.4% over three months, down 68.4% year to date and down 20.1% over the past year. It trades 76.8% below its 52-week high of $94.90 and 6.2% above its 52-week low of $20.73. The close sits below its 50-day moving average ($39.14) and below its 200-day moving average ($51.22).
NextPick tracks GPCR in its GLP-1 / Obesity basket alongside LLY, NVO, HIMS, VKTX and ALT. As of Oct 19, 2026, the basket's money-flow score is -62 (strong outflow), and the basket is down 6.0% over five sessions. Over the past month GPCR ranks 6th of 6 basket members by price change.
No — the Oct 19, 2026 close of $22.01 is 57.0% below the 200-day average of $51.22.
GPCR closed 76.8% below its 52-week high of $94.90.
NextPick groups GPCR with LLY, NVO, HIMS, VKTX and ALT in its GLP-1 / Obesity basket.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
